Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tilray is a drug manufacturers-specialty & generic business based in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Tilray employs 1,750 staff and has a trailing 12-month revenue of around $602.5 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $3.14 |
|---|---|
| 52-week range | $2.52 - $9.08 |
| 50-day moving average | $3.32 |
| 200-day moving average | $3.71 |
| Wall St. target price | $4.38 |
| PE ratio | 7.7143 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.42 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.14 from 2023-02-07
| 1 week (2023-02-01) | -5.71% |
|---|---|
| 1 month (2023-01-06) | 6.44% |
| 3 months (2022-11-08) | -17.37% |
| 6 months (2022-08-08) | -26.98% |
| 1 year (2022-02-04) | -47.23% |
|---|---|
| 2 years (2021-02-08) | -89.56% |
| 3 years (2020-02-07) | 16.915 |
| 5 years (2018-02-04) | N/A |
Valuing Tilray stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tilray's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tilray's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Tilray shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $602.5 million |
|---|---|
| Gross profit TTM | $116.8 million |
| Return on assets TTM | -2.38% |
| Return on equity TTM | -11.9% |
| Profit margin | -95.91% |
| Book value | $7.29 |
| Market capitalisation | $2 billion |
TTM: trailing 12 months
We're not expecting Tilray to pay a dividend over the next 12 months.
Tilray's shares were split on 2 May 2021. This wouldn't directly have changed the overall worth of your Tilray shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Tilray shares which in turn could have impacted Tilray's share price.
Over the last 12 months, Tilray's shares have ranged in value from as little as $2.52 up to $9.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.6198. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
